Results 161 to 170 of about 10,843 (242)

Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data. [PDF]

Blood Adv
Badawy SM, Palmblad J, Tricta F, Toiber Temin N, Fradette C, Lin L, Rozova A, Sheth S.   +7 more
europepmc   +1 more source

Design and development of metal-organic framework-based nanocomposite hydrogels for quantification of deferiprone in exhaled breath condensate. [PDF]

BMC Chem
Moharami R, Karimzadeh Z, Soleymani J, Jouyban-Gharamaleki V, Khoubnasabjafari M, Rahimpour E, Jouyban A.   +6 more
europepmc   +1 more source

Retraction to: The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy

, 2023
Shalini S. Rao, Stuart Portbury, Larissa Lago, Ashley I. Bush, Paul A. Adlard   +4 more
openalex   +2 more sources

Mitochondrial dysfunction, iron accumulation, lipid peroxidation, and inflammasome activation in cellular models derived from patients with multiple sclerosis. [PDF]

Aging (Albany NY)
García-Salas R, Cilleros-Holgado P, Di Spirito A, Gómez-Fernández D, Piñero-Pérez R, Romero-Domínguez JM, Álvarez-Córdoba M, Reche-López D, Romero-González A, López-Cabrera A, Sánchez-Alcázar JA.   +10 more
europepmc   +1 more source

Iron mobilisation from transferrin by deferiprone (L1) [PDF]

British Journal of Haematology, 2005
Kontoghiorghes, G J, Kolnagou, A, Eracleous, E, Evans, R W   +3 more
openaire   +4 more sources

Polydatin and Nicotinamide Prevent Iron Accumulation and Lipid Peroxidation in Cellular Models of Mitochondrial Diseases. [PDF]

Antioxidants (Basel)
Cilleros-Holgado P, Gómez-Fernández D, Piñero-Pérez R, Romero-Domínguez JM, Reche-López D, Álvarez-Córdoba M, Romero-González A, López-Cabrera A, De Oliveira MC, Rodríguez-Sacristán A, González-Granero S, García-Verdugo JM, Sánchez-Alcázar JA.   +12 more
europepmc   +1 more source

SCREENING THE HEPATOPROTECTIVE DOSE OF DEFERIPRONE AGAINST CONCANAVALIN A-INDUCED ACUTE HEPATOTOXICITY

, 2016
Dalia El‐Khouly
openalex   +1 more source

Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer. [PDF]

Cancer Discov
Sandoval TA, Salvagno C, Chae CS, Awasthi D, Giovanelli P, Marin Falco M, Hwang SM, Teran-Cabanillas E, Suominen L, Yamazaki T, Kuo HH, Moyer JE, Martin ML, Manohar J, Kim K, Sierra MA, Ramos Y, Tan C, Emmanuelli A, Song M, Morales DK, Zamarin D, Frey MK, Cantillo E, Chapman-Davis E, Holcomb K, Mason CE, Galluzzi L, Ni Zhou Z, Vähärautio A, Cloonan SM, Cubillos-Ruiz JR.   +31 more
europepmc   +1 more source

Deferoxamine, deferasirox, and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a randomised clinical trial. [PDF]

Lancet Reg Health Southeast Asia
Premawardhena A, Wanasinghe S, Perera C, Wijethilaka MN, Rajakaruna RHMG, Samarasinghe RANKK, Williams S, Mettananda S.   +7 more
europepmc   +1 more source

Iron chelation as a new therapeutic approach to prevent senescence and liver fibrosis progression. [PDF]

Cell Death Dis
Amengual J, Alay A, Vaquero J, Gonzalez-Sanchez E, Bertran E, Sánchez A, Herrera B, Meyer K, Maus M, Serrano M, Martínez-Chantar ML, Fabregat I.   +11 more
europepmc   +1 more source